Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1):18-38

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Estratti
Permessi
Per citare questo articolo

 

REVIEWS  SECOND GENERATION PET TRACERS IN ONCOLOGY 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2015 March;59(1):18-38

Copyright © 2015 EDIZIONI MINERVA MEDICA

lingua: Inglese

89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?

Van Dongen G. A., Huisman M. C., Boellaard R., Harry Hendrikse N., Windhorst A. D., Visser G. W., Molthoff C. F., Vugts D. J.

Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands


PDF


Positron emission tomography (PET) with 89Zr-labeled monoclonal antibodies (mAbs) or other targeted vehicles (e.g., peptides, nanoparticles and cells), collectively called “89Zr-immuno-PET”, can be used for better understanding of disease targets and the in vivo behavior of targeted drugs. This will become increasingly important in the development of next generation mAbs, which are characterized by high potency and/or multiple binding domains. This review provides practical information for researchers who want to implement 89Zr-immuno-PET for answering their own biological and pathological questions or for steering their own drug development program. An overview is given of the reagents, labeling protocols, quality tests and critical steps to come to high quality 89Zr-conjugates, while possibilities for further improvement are discussed. Since PET has the advantage of allowing quantitative imaging, information is provided about standardization of 89Zr quantification. Issues are summarized for consideration when starting preclinical or clinical 89Zr-immuno-PET studies, to enable at the end unequivocal interpretation of results. Finally, many appealing examples are provided of what can be learned from 89Zr-immuno-PET studies, while future directions are outlined. Most of the current examples are still on the characterization of mAbs in oncology, but the review will show that 89Zr-immuno-PET harbors potential for many kinds of targeted drugs and diseases, as well as for elucidating biological processes.

inizio pagina